Technavio analysts forecast the global gastroparesis drugs marketto reach USD 7,116.71 million by 2021 during the forecast period, according to their latest report.
This Smart News Release features multimedia. View the full release here: http://www.businesswire.com/news/home/20170516006555/en/
Technavio has published a new report on the global gastroparesis drugs market from 2017-2021. (Graphic: Business Wire)
The research study covers the present scenario and growth prospects of the global gastroparesis drugs market for 2017-2021. The report further segments the market based on drug class (prokinetic agents, antiemetic agents, and botulinum toxin injection), disease type (diabetic gastroparesis and idiopathic gastroparesis), and geography (the Americas, APAC, and EMEA).
Global gastroparesis drug market is expected to fetch profit from the growing incidence of diabetes, which is the most common known cause of gastroparesis. Rising diabetic population will propel the global gastroparesis market especially in regions such as APAC, which is primarily due to the large geriatric population residing in the region. The economic boom in emerging countries such as India and China has attracted many investors in the healthcare sector, leading to the growth of the global gastroparesis drugs market.
Looking for more information on this market? Request a free sample report
Technavio's sample reports are free of charge and contain multiple sections of the report including the market size and forecast, drivers, challenges, trends, and more.
Technavio healthcare and life sciencesanalysts highlight the following three factors that are contributing to the growth of the global gastroparesis drugs market
- The rising cases of diabetes fueling the prevalence of diabetic gastroparesis
- Rising gastric surgeries fueling the prevalence rate of post-surgical gastroparesis
- Unmet need in the industry to increase the R&D in the field
The rising cases of diabetes fueling the prevalence of diabetic gastroparesis
Diabetes is turning out to be one of the most serious health concerns for people across the world. The year 2015 recorded around 400-425 million people affected by diabetes; the number is expected to rise to around 625-650 million by 2040.
Barath Palada, a lead cardiovascular and metabolic disorders research analyst at Technavio, says, "As of 2015, more than 50% of the global diabetic patients were from APAC. Africa, however, will witness the highest growth in diabetes mainly due to rise in the lack of awareness and treatment facilities in the region. Globally, about half of the diabetic patients are undiagnosed, which indicates that the actual number may be higher than the estimated. Diabetes acts as one of the major factors leading to gastroparesis. The rising prevalence of diabetes is expected to propel the gastroparesis market directly
Rising gastric surgeries fueling the prevalence rate of post-surgical gastroparesis
The third most common type of gastroparesisafter idiopathic and diabetic gastroparesis is Post-surgical gastroparesis. Gastric surgeries include surgeries that are done to digestive parts of the bodies such as the esophagus, duodenum, and stomach. There is a high chance of the vagus nerves getting injured during the gastric surgery, and these injured nerves give rise to gastroparesis.
"Gastric bypass surgeries and bariatric surgeries are some of the common types of gastric surgeries. Rising obesity is a major reason for these surgeries as these surgeries are mainly performed for reducing weight," adds Barath.
Unmet need in the industry to increase the R&D in the field
At present, there are not much options available for the treating gastroparesis. This treatment is insufficient when compared with the prevalence of the disease. Gastroparesis is a common problem associated with diabetic patients, which adversely affects the quality of life. As of now, the diabetic gastroparesis has only one US FDA-approved drug for its treatment. This creates a highly unmet need in the market. Therefore, companies are trying to bring up newer therapeutics for the treatment. Fast-track approvals and recent studies are expected to drive the market during the forecast period.
Top vendors:
- Cadila Pharmaceuticals
- GlaxoSmithKline
- Johnson Johnson
- Valeant
Browse Related Reports:
- Global ENT Disorder Treatment Market 2017-2021
- Global Neutropenia Treatment Market 2017-2021
- Global Swine Health Market 2017-2021
Become a Technavio Insights member and access all three of these reports for a fraction of their original cost. As a Technavio Insights member, you will have immediate access to new reports as they're published in addition to all 6,000+ existing reports covering segments like orthopedics and medical devicesin-vitro diagnostics, and cardiovascular devices. This subscription nets you thousands in savings, while staying connected to Technavio's constant transforming research library, helping you make informed business decisions more efficiently.
About Technavio
Technavio is a leading global technology research and advisory company. The company develops over 2000 pieces of research every year, covering more than 500 technologies across 80 countries. Technavio has about 300 analysts globally who specialize in customized consulting and business research assignments across the latest leading edge technologies.
Technavio analysts employ primary as well as secondary research techniques to ascertain the size and vendor landscape in a range of markets. Analysts obtain information using a combination of bottom-up and top-down approaches, besides using in-house market modeling tools and proprietary databases. They corroborate this data with the data obtained from various market participants and stakeholders across the value chain, including vendors, service providers, distributors, re-sellers, and end-users.
If you are interested in more information, please contact our media team at media@technavio.com.
View source version on businesswire.com: http://www.businesswire.com/news/home/20170516006555/en/
Contacts:
Technavio Research
Jesse Maida
Media Marketing Executive
US: +1 630 333 9501
UK: +44 208 123 1770
www.technavio.com
